Raymond Dwek Sells 4,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Raymond Dwek sold 4,000 shares of United Therapeutics stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at approximately $497,962.50. The trade was a 69.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Trading Up 0.8 %

Shares of NASDAQ:UTHR traded up $2.27 during mid-day trading on Friday, reaching $281.16. The stock had a trading volume of 670,796 shares, compared to its average volume of 453,395. The company has a market cap of $12.63 billion, a P/E ratio of 12.35, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The business's 50 day moving average price is $323.22 and its 200 day moving average price is $351.14. United Therapeutics Co. has a 1 year low of $230.39 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same period in the prior year, the company earned $4.36 EPS. Analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $388.25.

Institutional Trading of United Therapeutics

A number of institutional investors have recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the 4th quarter worth approximately $25,000. Dunhill Financial LLC increased its stake in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares during the period. State of Wyoming purchased a new position in shares of United Therapeutics during the fourth quarter worth $62,000. Millstone Evans Group LLC acquired a new position in United Therapeutics during the fourth quarter valued at $67,000. Finally, Curat Global LLC purchased a new stake in United Therapeutics in the first quarter valued at $63,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.